Miniaturized IL-2/anti-IL-2 immunocytokines selectively activate and support the in vivo persistence of regulatory T cells
Taken together, our findings position miniF5111 IC as a versatile platform to selectively target and activate specific immune cell subsets, demonstrating its potential as a next-generation therapeutic to treat autoimmune disorders and prevent transplant rejection.
Authors
- Jakub Tomala (ORCID: https://orcid.org/0000-0002-6315-2832)
- Bailey T. Chalmers
- Emily Ariail
- Paul Zdinak
- Ella C. Teeley
- Jamie B. Spangler
- Charina S. Fabilane
- A. Carson Stephenson
- Alok V. Joglekar
Institutions
- Bloomberg (United States) (US)
- Johns Hopkins University (US)
- University of Pittsburgh (US)
- Johns Hopkins Medicine (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-03-09
- DOI
- https://doi.org/10.3389/fimmu.2026.1755812
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Science Foundation
- U.S. Department of Defense
- Damon Runyon Cancer Research Foundation
- CureSearch for Children's Cancer
- Leona M. and Harry B. Helmsley Charitable Trust
- University of Pittsburgh
- Kenneth Rainin Foundation
- National Institutes of Health
- Advanced Research Projects Agency